Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Letter to the Editor

Drug Re-purposing from SARS-CoV Led the Identification of Potential Candidate Drug Target and Alternate Drug Molecules Against SARSCoV- 2

Author(s): PV Parvati Sai Arun*, Razak Hussain, Yusuf Akhter, Mandava Venkata Basaveswara Rao, Perugu Shyam and Sailu Yellaboina

Volume 17, Issue 10, 2020

Page: [1325 - 1327] Pages: 3

DOI: 10.2174/1570180817999200730190600

Abstract

Background: SARS-CoV-2 causes COVID19 disease where there are no suitable drugs available.

Objective: The objective of the work is to repurpose the drugs prescribed for SARS-CoV as the drugs for the control of SARS-CoV-2.

Methods: In this work, we have used homology searches and docking methods for understanding the mechanism of the drugs prescribed for the control of SARS-CoV on SARS-CoV-2.

Results: In our analysis, we found that the drugs Benzyl (2-Oxopropyl)carbamate, 2-[(2,4-Dichloro- 5-methyl phenyl)sulfonyl]-1,3-dinitro-5-(trifluoromethyl)benzene, S-[5-(Trifluoromethyl)-4H-1,2,4- triazol-3-YL] 5-(phenylethynyl)furan-2-carbothioate, 4-(Dimethylamino)benzoic acid, which are capable of inhibition of the activity of 3CLPro and prevent the progression of SARS-CoV.

Conclusion: In this letter, we describe the findings of the protein ligand interactions between 3CLPro of SARS-CoV, SARS-CoV-2 with Benzyl (2-oxopropyl) carbamate.

Keywords: Drugs, repurposing, SARS-CoV, SARS-CoV-2, 3CLpro, Benzyl(2-oxopropyl) carbamate.

« Previous
Graphical Abstract

[1]
Baden, L.R.; Rubin, E.J. Covid-19-The Search for Effective Therapy; Mass Medical Soc, 2020.
[http://dx.doi.org/10.1056/NEJMe2005477]
[2]
Gautret, P.; Lagier, J-C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, 56(1), 105949.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[3]
Munster, V.J.; Koopmans, M.; van Doremalen, N.; van Riel, D.; de Wit, E. A novel coronavirus emerging in China-key questions for impact assessment. N. Engl. J. Med., 2020, 382(8), 692-694.
[http://dx.doi.org/10.1056/NEJMp2000929] [PMID: 31978293]
[4]
Zhou, P.; Yang, X-L.; Wang, X-G.; Hu, B.; Zhang, L.; Zhang, W. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv, 2020, 1(22), 914952.
[http://dx.doi.org/10.1038/s41586-020-2012-7]
[5]
Perlman, S. Another decade, another coronavirus. New. Engl. J. Med., 2020, 382(8)
[http://dx.doi.org/ 10.1056/NEJMe2001126] [http://dx.doi.org/10.1056/NEJMe2001126]
[6]
Bacha, U.; Barrila, J.; Gabelli, S.B.; Kiso, Y.; Mario Amzel, L.; Freire, E. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem. Biol. Drug Des., 2008, 72(1), 34-49.
[http://dx.doi.org/10.1111/j.1747-0285.2008.00679.x] [PMID: 18611220]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy